Skip to content
Review Open access

The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials

Sep 2026 · Cureus · Vol 18 · 0 citations · 12 references
Medicine

TL;DR

The findings of this meta-analysis support Etrasimod as an effective and well-tolerated treatment option for achieving and maintaining remission in patients with moderate to severe UC.

Abstract

Etrasimod is a selective sphingosine 1-phosphate (S1P) receptor modulator that is used as a novel oral treatment for moderate to severe ulcerative colitis (UC). The efficacy and safety of Etrasimod across both induction and maintenance treatment phases require further evaluation. An extensive search was conducted across PubMed, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials (CENTRAL), identifying seven reports of five independent randomised controlled trials (RCTs) comprising 1230 participants across multiple countries to be included in this meta-analysis. Data analysis was carried out using a fixed-effects model, with results reported as risk ratios (RRs) and 95% confidence intervals (CIs). Etrasimod significantly increased the likelihood of clinical remission at Week 12 (RR 2.63; 95% CI: 1.91, 3.62; p-value < 0.00001) and beyond 40 weeks (RR 2.87; 95% CI: 1.89, 4.37; p-value < 0.00001). Clinical response also improved significantly at Week 12 (RR 1.68; 95% CI: 1.44, 1.95; p-value < 0.00001) and beyond 40 weeks (RR 1.73; 95% CI: 1.35, 2.21; p-value < 0.0001). Etrasimod significantly improved endoscopic outcomes at Week 12 (RR 2.15; 95% CI: 1.67, 2.75; p-value < 0.00001) and beyond 40 weeks (RR 2.57; 95% CI: 1.79, 3.68; p-value < 0.00001). Significant improvements were also observed in symptomatic remission at Week 12 (RR 1.81; 95% CI: 1.47, 2.24; p-value < 0.00001) and beyond 40 weeks (RR 1.96; 95% CI: 1.47, 2.61; p-value < 0.00001), as well as mucosal healing at Week 12 (RR 2.67; 95% CI: 1.77, 4.02; p-value < 0.00001) and beyond 40 weeks (RR 2.62; 95% CI: 1.69, 4.04; p-value < 0.0001). Steroid-free clinical remission was also significantly more likely with Etrasimod (RR 3.83; 95% CI: 2.21, 6.62; p-value < 0.00001). No statistically significant difference was observed in serious adverse events between Etrasimod and placebo (RR 1.06; 95% CI: 0.61, 1.85; p-value = 0.83), although a small increase in other adverse events was observed with Etrasimod (RR 1.15; 95% CI: 1.03, 1.28; p-value = 0.01). No deaths were reported in either treatment group. The findings of this meta-analysis support Etrasimod as an effective and well-tolerated treatment option for achieving and maintaining remission in patients with moderate to severe UC. Further research will help to better understand the long-term effects and safety of Etrasimod in patients with different disease characteristics, comorbidities and potential drug interactions.

Read PDF

Similar papers

Review Open access Sep 2026

Efficacy and Safety of Mirikizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Objective: Mirikizumab, a p19-directed anti-interleukin-23 monoclonal antibody, has been evaluated as induction and maintenance therapy for moderately to severely active ulcerative colitis (UC). We conducted a systematic review and meta-analysis of randomized, placebo-controlled trials to quantify its efficacy and safe...

G. Dağcı, A. Sarıca, B. F. Ağargün et al. · 0 citations
Review Oct 2026

EFFICACY AND SAFETY OF ADVANCED THERAPIES AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.

BACKGROUND & AIMS Advanced therapies (ATs) are central to the management of moderate-to-severe ulcerative colitis (UC). The expanding therapeutic landscape and limited head-to-head trials necessitate updated comparative effectiveness analyses. We performed a systematic review and network meta-analysis (NMA) to assess t...

Pablo A. Olivera, Juan S. Lasa, Siddharth Singh et al. · 0 citations
Meta-analysis Open access Sep 2026

Cutaneous efficacy and glucocorticoid-sparing effects of anifrolumab in systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials

Objective To evaluate the cutaneous efficacy and glucocorticoid-sparing effects of anifrolumab in systemic lupus erythematosus (SLE) and to assess composite disease activity and flare-related and safety outcomes. Methods PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched through...

Jia-Ni Wang, Fei Liu, Q. Lou et al. · 0 citations
Review Open access Oct 2026

Efficacy and Safety of Remogliflozin in Adults with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis

Introduction: Remogliflozin is a sodium–glucose cotransporter-2 inhibitor used for type 2 diabetes mellitus (T2DM), but its overall efficacy and safety remain fragmented. This updated systematic review and meta-analysis evaluated the efficacy and safety of remogliflozin using evidence exclusively from randomized contro...

N. Kostadinov, T. Totomirova, Z. Kirovakov et al. · 0 citations
Review Open access 2026

Efficacy and safety of icotrokinra (JNJ2113) for moderate-to-severe plaque psoriasis: a systematic review and metaanalysis of randomized controlled trials

Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs and offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time.

M. Alkharisi, Yara Ayman Zein, F. Alammari et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.